{"Clinical Trial ID": "NCT00005879", "Intervention": ["INTERVENTION 1:", "- Placebo", "- Placebo", "Placebo: dialysis-matched tablet", "INTERVENTION 2:", "- Arzoxifene", "LY353381, 20 mg daily", "1 tablet a day"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "The current random aspiration from the breast to the fine needle (AFN) is evidence of 1 of the following:", "Hyperplasia with atypy", "\u2022 Hyperplasia without atypia but with a modified Gail risk of at least 10 years of at least 4%", "Hyperplasia without atypia but with a BRCAPRO risk of at least 25%", "Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2", "Hyperplasia without atypia but with a history of contralateral in situ canal carcinoma or invasive breast cancer", "The ANF must have been taken during days 1-14 of the menstrual cycle in premenopausal women.", "If the uterus and/or intact ovaries must have a doppler-coloured transvaginal pelvic sonography within the last 6 months showing an endometrial thickening not exceeding 13 mm before menopause or not exceeding 8 mm after menopause", "No ovarian cyst appeared to be possible or probably non-physiological that did not resolve the satisfaction of the gynecologist on the repeated sonogram", "\u2022 Must agree to conduct or have had genetic consultations and tests carried out for BRCA1 and BRCA2", "No active cancer (e.g. detectable disease)", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age:", "- 18 years and over", "Gender:", "Women", "Status of menopause:", "Any", "Status:", "Unspecified", "Life expectancy:", "At least 12 months", "Haematopoietic:", "Hemoglobin greater than 10 g/dL", "Number of granulocytes greater than 1000/mm^3", "No protein deficiency C, S or antithrombin III", "No resistance to activated protein C", "Hepatic:", "\u2014 Albumin greater than 3,0 g/dL", "Bilirubine less than 1.5 mg/dL", "ASAT less than 100 U/L", "- Alkaline phosphatase less than 200 U/L", "- Renal:", "Creatinine less than 1.5 mg/dL", "Cardiovascular disorders:", "No history of deep venous thrombosis unrelated to trauma or pregnancy", "No serious coronary artery disease", "No history of stroke", "Other:", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception during and for 3 months after the study.", "No other active cancers", "No retinal venous thrombosis", "No severe and concomitant migraine, poorly controlled", "No transfer-carrying Leiden V factor", "THERAPE PRIOR CONCURENT:", "Biological therapy:", "At least 12 months after previous immunotherapy", "- Chemotherapy:", "At least 3 months between the completion of the phase II pre-study of KUMC on difluoromethylornithine (DFMO) and the initial aspiration", "At least 12 months after previous chemotherapy", "Endocrinotherapy:", "Do not start or stop hormone replacement therapy or oral contraceptives within 6 months of initial aspiration", "\u2022 Should continue all hormone replacement and/or oral contraceptive treatments that were taken at the time of initial aspiration", "At least 12 months since tamoxifen, raloxifene or other hormone treatments", "Radiotherapy:", "At least 3 months after previous radiation therapy", "Surgery:", "At least 6 months between the anterior ophorectomy and the initial aspiration", "Other:", "At least 2 weeks after the start of another new medicine that would be ingested for 1 month or more"], "Results": ["Performance measures:", "Change in Masood score", "Change in the semi-quantitative score assigned by the designated cytopathologist.", "Range 6-24. The score represents a growing anomaly (i.e. worse appearance) Composite sum of 6 cytomorphological characteristics, each with a score of 1 to 4.", "Time limit: reference to 6 months", "Results 1:", "Title of the arm/group: Placebo", "Description of the arm/group: Placebo", "Placebo: dialysis-matched tablet", "Total number of participants analysed: 84", "Average (standard deviation)", "Unit of measurement: units on a scale -1.1 (1.9)", "Results 2:", "Title of the arm/group: Arzoxifene", "Description of the arm/group: LY353381, 20 mg per day", "1 tablet a day", "Total number of participants analysed: 82", "Average (standard deviation)", "Unit of measurement: units on a scale -0.8 (2.1)"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/101 (4.95%)", "BILATERAL CATARACTS * 0/101 (0.00 %)", "ANNEX * 2/101 (1.98%)", "ICHEMICAL COULITIS * 1/101 (0.99%)", "ELECTRONIC DISCUSSION * 0/101 (0.00 %)", "* 0/101 (0.00 per cent)", "* 0/101 (0.00 per cent)", "CANCER BREAST * 0/101 (0.00 %)", "* 0/101 (0.00 %)", "CYST OVARIEN * 1/101 (0.99%)", "Adverse Events 2:", "Total: 9/98 (9.18 per cent)", "BILATERAL CATARACTS * 1/98 (1.02%)", "ANNEX * 0/98 (0.00 %)", "* 0/98 (0.00 %)", "SLIPPED DISQUE * 1/98 (1.02%)", "BIMALLEOLARY SECTION OF LAW * 1/98 (1.02%)", "* 1/98 (1.02%)", "* 1/98 (1.02%)", "* 1/98 (1.02%)", "CYST OVARIEN * 1/98 (1.02%)"]}